Metagenomi Therapeutics, Inc. (MGX)
MGX moved a median of 0.00% 30 minutes after news, and -0.92% by the close. How MGX actually reacts to news — the realized, point-in-time move the market made, measured across 880 labeled events over the last three years with zero look-ahead.
MGX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 823 |
| 30-min | 0.00% | 45% | 876 |
| 60-min | -0.03% | 45% | 879 |
| to close | -0.92% | 33% | 878 |
| Middle 50% of MGX reactions | -1.52% to +1.06% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 880 |
Half of all Metagenomi Therapeutics, Inc. news events land between -1.52% and +1.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MGX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 11 | -0.77% | 27% | -0.69% |
| Coverage initiations | 21 | -2.45% | 14% | -4.98% |
| Rating reiterations | 36 | +0.46% | 56% | +1.07% |
| Price-target cuts | 10 | -1.06% | 30% | +0.17% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how MGX ranks against every other measured name →
That’s how MGX usually reacts — get an email when it moves on news →Email me when MGX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MGX's baseline. Nothing else.
Recent MGX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference | Press release | GlobeNewswire | -1.76% | -10.07% | |
| Form 8-K Metagenomi Therapeutics, For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | +3.74% | +6.54% | |
| Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | -0.84% | -1.68% | |
| Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | — | -2.42% | |
| Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio | Press release | GlobeNewswire | +1.51% | -2.27% | |
| Form 8-K Metagenomi Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.63% | +0.00% | |
| Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | +1.57% | +0.79% | |
| Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | +4.48% | |
| Form 10-Q Metagenomi Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.54% | +3.85% | |
| Form 8-K Metagenomi Therapeutics, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +1.54% | +3.85% | |
| Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.54% | +3.85% | |
| Form ARS Metagenomi Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -0.69% | |
| Form DEF 14A Metagenomi Therapeutics, For: Apr 21 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.69% | |
| Form DEFA14A Metagenomi Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -0.69% | |
| Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency | Press release | GlobeNewswire | +1.42% | +2.13% | |
| Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | — | +0.00% | |
| Form 10-K Metagenomi Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.57% | -4.52% | |
| Form 8-K Metagenomi Therapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -2.57% | -4.52% | |
| Form S-8 Metagenomi Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -2.57% | -4.52% | |
| Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.57% | -4.52% | |
| Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference | Press release | GlobeNewswire | +1.43% | +6.38% | |
| Form 8-K Metagenomi, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.92% | -2.23% | |
| Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook | Press release | GlobeNewswire | -3.92% | -2.23% | |
| Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference | Press release | GlobeNewswire | -3.80% | -6.43% | |
| Metagenomi to Present at Jefferies Global Healthcare Conference in London | Press release | GlobeNewswire | -1.16% | -1.16% | |
| Form 10-Q Metagenomi, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -6.00% | -7.00% | |
| Form 8-K Metagenomi, Inc. For: Nov 11 | SEC filing · Form 8-K | SEC EDGAR | -6.00% | -7.00% | |
| Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development | Press release | GlobeNewswire | -6.00% | -7.00% | |
| Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates | Press release | GlobeNewswire | -6.00% | -7.00% | |
| Form 8-K Metagenomi, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -1.22% | +1.63% | |
| Form 10-Q Metagenomi, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.08% | +1.04% | |
| Form 8-K Metagenomi, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | +1.04% | |
| Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -2.08% | +1.04% | |
| Metagenomi Appoints Laurence Reid, PhD to its Board of Directors | Press release | GlobeNewswire | -0.82% | — | |
| Form 8-K Metagenomi, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -3.19% | -5.10% | |
| Form 8-K Metagenomi, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -2.48% | -6.83% | |
| Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025 | Press release | GlobeNewswire | -2.48% | -6.83% | |
| Form 10-Q Metagenomi, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.48% | -6.83% | |
| Form 8-K Metagenomi, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -2.48% | -6.83% | |
| Metagenomi Reports Business Updates and First Quarter 2025 Financial Results | Press release | GlobeNewswire | -2.48% | -6.83% | |
| Metagenomi to Present at Upcoming Scientific Meetings | Press release | GlobeNewswire | +0.67% | +8.05% | |
| Form ARS Metagenomi, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -2.37% | |
| Form DEF 14A Metagenomi, Inc. For: Apr 25 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -2.37% | |
| Form DEFA14A Metagenomi, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -2.37% | |
| Form EFFECT Metagenomi, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.01% | -1.24% | |
| Form 10-K Metagenomi, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.87% | -6.49% | |
| Form 8-K Metagenomi, Inc. For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | -4.87% | -6.49% | |
| Form S-3 Metagenomi, Inc. | SEC filing · Form S-3 | SEC EDGAR | -4.87% | -6.49% | |
| Form S-8 Metagenomi, Inc. | SEC filing · Form S-8 | SEC EDGAR | -4.87% | -6.49% | |
| Metagenomi Reports Business Updates and Full Year 2024 Financial Results | Press release | GlobeNewswire | -4.87% | -6.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MGX section they belong to.
Where else MGX is measured.
MGX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Metagenomi Therapeutics, Inc.'s median reaction calculated?
Every labeled MGX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 880 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of MGX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MGX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.